316 related articles for article (PubMed ID: 28155013)
1. Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).
Pettijohn EM; Ma S
Curr Hematol Malig Rep; 2017 Feb; 12(1):20-28. PubMed ID: 28155013
[TBL] [Abstract][Full Text] [Related]
2. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
Hill RJ; Lou Y; Tan SL
Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
[TBL] [Abstract][Full Text] [Related]
3. Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents.
Maly J; Blachly JS
Curr Hematol Malig Rep; 2016 Feb; 11(1):52-60. PubMed ID: 26893063
[TBL] [Abstract][Full Text] [Related]
4. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
5. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
McCaig AM; Cosimo E; Leach MT; Michie AM
Br J Haematol; 2011 Apr; 153(2):199-211. PubMed ID: 21352196
[TBL] [Abstract][Full Text] [Related]
7. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
8. Towards targeted therapy of chronic lymphocytic leukemia.
Niemann CU; Jones J; Wiestner A
Adv Exp Med Biol; 2013; 792():259-91. PubMed ID: 24014301
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.
Abou Zahr A; Bose P; Keating MJ
Expert Opin Pharmacother; 2017 Jun; 18(9):857-873. PubMed ID: 28446054
[TBL] [Abstract][Full Text] [Related]
10. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Varma G; Johnson TP; Advani RH
Clin Adv Hematol Oncol; 2016 Jul; 14(7):543-54. PubMed ID: 27379948
[TBL] [Abstract][Full Text] [Related]
11. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
Davids MS; Brown JR
Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
[TBL] [Abstract][Full Text] [Related]
12. Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
Mato A; Jauhari S; Schuster SJ
Am J Hematol; 2015 Jul; 90(7):657-64. PubMed ID: 25808792
[TBL] [Abstract][Full Text] [Related]
13. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Buchner M; Fuchs S; Prinz G; Pfeifer D; Bartholomé K; Burger M; Chevalier N; Vallat L; Timmer J; Gribben JG; Jumaa H; Veelken H; Dierks C; Zirlik K
Cancer Res; 2009 Jul; 69(13):5424-32. PubMed ID: 19549911
[TBL] [Abstract][Full Text] [Related]
14. [Reaserch Advance on Inhibitor Targeting at the B-Cell Receptor Pathway in Chronic Lymphocytic Leukemia --Review].
Ji TT; Chen QN; Tao SD; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):708-712. PubMed ID: 32319422
[TBL] [Abstract][Full Text] [Related]
15. Novel treatments for chronic lymphocytic leukemia and moving forward.
Brown JR; Porter DL; O'Brien SM
Am Soc Clin Oncol Educ Book; 2014; ():e317-25. PubMed ID: 24857119
[TBL] [Abstract][Full Text] [Related]
16. BCL-2 Inhibitors, Present and Future.
Ryan CE; Davids MS
Cancer J; 2019; 25(6):401-409. PubMed ID: 31764121
[TBL] [Abstract][Full Text] [Related]
17. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Feng G; Wang X
Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
[TBL] [Abstract][Full Text] [Related]
18. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies.
Lukas M; Velten B; Sellner L; Tomska K; Hüellein J; Walther T; Wagner L; Muley C; Wu B; Oleś M; Dietrich S; Jethwa A; Bohnenberger H; Lu J; Huber W; Zenz T
Leukemia; 2020 Nov; 34(11):2934-2950. PubMed ID: 32404973
[TBL] [Abstract][Full Text] [Related]
19. BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
Daniel C; Mato AR
Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276
[TBL] [Abstract][Full Text] [Related]
20. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
Robak P; Robak T
Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]